Analysis of ERCC1 levels in Tet-on ERCC1 tumors. ERCC1 expression in (A) HCT116-Tet-on and (B) COLO205-Tet-on tumors were determined following subcutaneous injections in mice and prior to an IP injection with doxycycline at 10 or 50 mg/kg. Tumors extracts were collected to detect ERCC1 and β-actin levels.

Figure 3. The correlation between the changes in ERCC1 expression level and radiation resistance. The cell extracts were collected from (A) HCT116-Tet-on-ERCC1 or (B) COLO205-Teton-ERCC1 cells treated with 0, 0.5, 1, or 2 μg/mL doxycycline for 24 h. Anti-ERCC1 or anti-β-actin mAbs were used to detect ERCC1 or β-actin. (C) COLO205-Tet-on and (D) HCT116-Tet-on cells were treated with 0, 0.5, 1, or 2 μg/mL doxycycline for 24 h following exposure to 8 Gy radiation for 48 h. Cell viability (%) = the luminescence units of the sample groups/the luminescence units of the control group mean × 100%. * indicates a significant difference, p < 0.05. The luminescence units were measured by multimode plate reader (VICTORTM X2, PerkinElmer).

13Briefly describe TWO treatment modalities for cancers.

La réponse immune anti-tumorale fait intervenirAUne activité métabolique intenseBLa sécrétion des facteurs spécifiques VEGFCL'immunité reproductiveDL'immunité adaptativeEL'élaboration de substances qui vont favoriser la multiplication des vaisseaux

Tumor microenvironment (TME)

The most feared property of malignant tumors are:A Metastasis B Contact inhibition C Apoptosis D Controlled division